TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05335096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational materials
Description: the research assistant will manually sent to the participants' phone a piece of educational material and an online survey link every 30 days (at days 30, 60, 90, 120, 150 and 180).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: the research assistant will manually sent to the participants' phone a piece of educational material and an online survey link every 30 days (at days 30, 60, 90, 120, 150 and 180).
Study: NCT05287568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2 that binds with \> 1,000-fold higher affinity to BCL-2 (Ki \< 0.010 nM) than other apoptotic pathway proteins BCL-XL (Ki = 48 nm) or MCL-1 (Ki \> 444 nM). Leukemia stem cells (LSCs) overexpress BCL-2, and BCL-2 overexpression has been associated with worse outcomes in AML.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2 that binds with \> 1,000-fold higher affinity to BCL-2 (Ki \< 0.010 nM) than other apoptotic pathway proteins BCL-XL (Ki = 48 nm) or MCL-1 (Ki \> 444 nM). Leukemia stem cells (LSCs) overexpress BCL-2, and BCL-2 overexpression has been associated with worse outcomes in AML.
Study: NCT05718934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine and glycopyrrolate
Description: See arm descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: See arm descriptions
Study: NCT05287568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2 that binds with \> 1,000-fold higher affinity to BCL-2 (Ki \< 0.010 nM) than other apoptotic pathway proteins BCL-XL (Ki = 48 nm) or MCL-1 (Ki \> 444 nM). Leukemia stem cells (LSCs) overexpress BCL-2, and BCL-2 overexpression has been associated with worse outcomes in AML.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.
Study: NCT05624788

Intervention type: OTHER
Intervention: No Intervention
Description: Participants who self-identify as American Indian or Alaska Native with any indication requiring referral to a specialist after a primary care provider standard of care visit will be observed to collect data, using several surveys at 6 and 12 months. No additional specialty care visits will be added for the purpose of this study given the intent to observe medical care received following primary care provider referral. Referral to a specialist will be based on local clinical practice.

Intervention type: OTHER
Intervention: No Intervention
Description: Participants who self-identify as American Indian or Alaska Native with any indication requiring referral to a specialist after a primary care provider standard of care visit will be observed to collect data, using several surveys at 6 and 12 months. No additional specialty care visits will be added for the purpose of this study given the intent to observe medical care received following primary care provider referral. Referral to a specialist will be based on local clinical practice.

Intervention type: OTHER
Intervention: No Intervention
Description: Participants who self-identify as American Indian or Alaska Native with any indication requiring referral to a specialist after a primary care provider standard of care visit will be observed to collect data, using several surveys at 6 and 12 months. No additional specialty care visits will be added for the purpose of this study given the intent to observe medical care received following primary care provider referral. Referral to a specialist will be based on local clinical practice.
Study: NCT05464914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEO Pack
Description: is a eugenol-free, surgical dressing and periodontal pack that has no burning sensation, no unpleasant taste or odor, and offers proven protection to surgical sites. This product promotes cleanliness and healing. Plastic and cohesive, ropes of any length or thickness can be formed. The smooth texture allows this product to adapt closely to the teeth and tissue in order to protect the wound. It sets with resilient, non-brittle hardness.
Study: NCT06256679

Intervention type: PROCEDURE
Intervention: superior hypogastric plexus pulsed radiofrequency and transcutaneous tibial nerve stimulation
Description: The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies. 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side. Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a transdiscal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds. Two 50x50 mm electrode pads were placed on the posterior-superior aspect of the medial malleolus for posterior tibial nerve stimulation. Stimulation was delivered in continuous mode at a frequency of 20 Hz and a pulsed width of 200 ms. It was applied once a week for 30 min for 4 weeks.

Intervention type: PROCEDURE
Intervention: superior hypogastric plexus pulsed radiofrequency
Description: The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies.~After negative aspiration of blood, 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side.~Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a trans discal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds.
Study: NCT06165887

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, no intervention will be implemented.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, no intervention will be implemented.
Study: NCT05047224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-assessment + in-person assessment
Description: Participants will complete a tele-assessment using the TAP. They will complete a traditional, in-person autism spectrum disorder assessment approximately two weeks later.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tele-assessment only
Description: Participants will complete a tele-assessment using the TAP. They will complete a second, shorter tele-assessment approximately two weeks later.
Study: NCT05494437

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PP-01 High Dose
Description: Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
Study: NCT05133999

Intervention type: BIOLOGICAL
Intervention: Plasma determination of iron, transferrin and ferritin
Description: Iron, transferrin and ferritin levels in plasma

Intervention type: OTHER
Intervention: Fundus Examination by wide field digital imaging camera (PanocamTM camera)
Description: ROP screening using wide field digital retinal imaging according to current recommendations.
Study: NCT06034613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-based mindfulness intervention for emotional distress(iMIED）
Description: The iMIED program integrates the rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from MBIs. In addition, the iMIED program selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks. In total, it took about 30 min per day to finish all the tasks. The program lasted for 49 days.
Study: NCT05177679

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active supplement
Description: Carotenoid supplement comprised of 10mg lutein and 2mg zeaxanthin.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo control supplement
Study: NCT05494437

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PP-01 Low Dose
Description: CB1 partial agonist / GABAergic modulator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nabilone
Description: CB1 receptor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: GABAergic modulator
Study: NCT05501717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2030
Description: ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2030
Description: ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2030
Description: ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2030
Description: ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2030
Description: ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.
Study: NCT04930887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel (Bupivacaine Liposome)
Description: Non-opioid postsurgical analgesic used in the management of postsurgical pain; 133 mg/10 mL (13.3 mg/mL) single-dose vial (per Pacira), study administers 3cc bilaterally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Prescription medicine used for fluid and electrolyte replenishment for intravenous administration; Exparel-matched Placebo treatment
Study: NCT05543486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levitation 2 Tri-Compartment Offloader (TCO) knee brace
Description: Spring Loaded Technology Levitation 2 Tri-Compartment Offloader (TCO) brace containing proprietary spring technology providing a knee extension assist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Knee sleeve
Description: Neenca soft knee sleeve comprised of elastic air knit fabric with a silicone padded patella inset and flexible stays on the medial and lateral sides.
Study: NCT06225726

Intervention type: PROCEDURE
Intervention: urethral bladder resection
Description: urethral bladder resection. Per-operative bladder ultrasound elastography and simultaneous cystometry
Study: NCT04862156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic Machine Perfusion (NMP)
Description: Storage and transportation of the donated liver using the OrganOx metra device.
Study: NCT05203263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (810A-v1) device prototype
Description: Sequence with Serial Number from (810-v1 101) to (810-v1 140). Application on brown spots located on the face (6 treatments during the study).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (810A-v1) device prototype
Description: Sequence with Serial Number from (810-v1 101) to (810-v1 140). Application on brown spots located on the face (6 treatments during the study).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (810B-v1) device prototype
Description: Sequence with Serial Number (810-v1 141) to (810-v1 160). Application on brown spots located on the face (6 treatments during the study).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (810C-v1) device prototype
Description: Sequence with Serial Number (810-v1 161) to (810-v1 200). Application on brown spots located on the face (6 treatments during the study).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: (810C-v1) device prototype
Description: Sequence with Serial Number (810-v1 161) to (810-v1 200). Application on brown spots located on the face (6 treatments during the study).
Study: NCT05059444

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Reveal
Description: Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Reveal
Description: Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Reveal
Description: Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Reveal
Description: Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Reveal
Description: Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Reveal
Description: Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Reveal
Description: Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Reveal
Description: Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Reveal
Description: Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Reveal
Description: Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Reveal
Description: Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.
Study: NCT04852887

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Description: Post lumpectomy radiation therapy will be external beam radiation to either the whole breast + boost, partial breast irradiation, or Accelerated Partial Breast Irradiation that must begin within 12 weeks of the last breast cancer surgery(including re-excision of margins).~Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s). Endocrine therapy may be initiated before, during, or after completion of radiation therapy at the discretion of the investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Description: Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s).
Study: NCT05085496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT05135494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: The Experimental Group will perform IMT which includes training of the inspiratory muscles with the PowerBreath Medic Plus regulated at 75% of the subjects' maximal inspiratory pressure (MIP) values, five times/week over five weeks 5 sets of 5 repetitions with 1 set increasing each week.~They will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control group will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA.
Study: NCT06212960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DWP712
Description: Clostridium botulinum Toxin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX®
Description: Clostridium botulinum Toxin
Study: NCT05359094

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Microcrystalline α-cellulose) supplement with a Plant-Dominant Low-Protein Diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Probiotics(Pediococcus acidilactici GKA4) supplement with a Plant-Dominant Low-Protein Diet
Study: NCT05426694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular clock exercises
Description: In scapular clock exercises, the hand is placed on the wall in front of your body. Move the hand in direction of 12 and 6 o'clock to elevate and depress the scapula. Then move hands towards 9 o' clock and 3 o'clock direction to protract and retract the scapula. Hold each position for 10 seconds. From 3rd week and onward the patient will use thera-band and then perform clock exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and strengthening exercises
Description: Stretching and strengthening exercises of shoulder and scapular muscles was performed including wall washes, corner stretch, pectoral muscles stretch and wall push ups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and strengthening exercises
Description: Stretching and strengthening exercises of shoulder and scapular muscles was performed including wall washes, corner stretch, pectoral muscles stretch and wall push ups.
Study: NCT05798663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given to participants either intravenously at a dosage of 1200mg or subcutaneously at a dosage of 1875 mg on Day 1 of each 21-day cycle for Arms A, B, and C, and on days 1 and 22 of concurrent chemoradiotherapy for Arm C only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given to participants either intravenously at a dosage of 1200mg or subcutaneously at a dosage of 1875 mg on Day 1 of each 21-day cycle for Arms A, B, and C, and on days 1 and 22 of concurrent chemoradiotherapy for Arm C only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given to participants either intravenously at a dosage of 1200mg or subcutaneously at a dosage of 1875 mg on Day 1 of each 21-day cycle for Arms A, B, and C, and on days 1 and 22 of concurrent chemoradiotherapy for Arm C only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be given to participants intravenously at a dosage of 600 mg on day 1 of each 21-day cycle (Arms B and C), and on days 1 and 22 of concurrent chemoradiotherapy (Arm C only).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be given to participants intravenously at a dosage of 600 mg on day 1 of each 21-day cycle (Arms B and C), and on days 1 and 22 of concurrent chemoradiotherapy (Arm C only).
Study: NCT06012071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia dental implants
Description: Dental implants produced from zirconia material, either wit tissue-level or bone-level platform.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zirconia dental implants
Description: Dental implants produced from zirconia material, either wit tissue-level or bone-level platform.